Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
41 Results for "
classical pathway
" in MedChemExpress (MCE) Product Catalog:
Products (41)
41 Results for "classical pathway" in MCE Product Catalog:
Cat. No.: HY-155851
CAS No.: 444914-19-6
Cat. No.: HY-P10669
CAS No.: 2999646-19-2
Cat. No.: HY-P990955
CAS No.: 2839652-75-2
Synonyms: ADX-097
Target:
Research Areas:
Cat. No.: HY-N21519
CAS No.: 2193052-99-0
Target:
Cat. No.: HY-N19128
CAS No.: 1476801-10-1
Target:
Cat. No.: HY-P992463
Target:
Research Areas:
Cat. No.: HY-P991022
CAS No.: 2842046-67-5
Synonyms: NM8074
Target:
Research Areas:
Cat. No.: HY-P992512
Target:
Research Areas:
ANX-M1 Mouse IgG1 is a brain-penetrant C1q inhibitor. ANX-M1 Mouse IgG1 blocks classical complement pathway activation, reduces C1q concentrations in brain and plasma, and inhibits microglia-mediated synapse engulfment. ANX-M1 Mouse IgG1 can be used for the research of Huntington's disease, Alzheimer's disease, retinopathy and neuropathic pain .
Cat. No.: HY-P991954
Target:
Research Areas:
Cat. No.: HY-N19716
CAS No.: 34427-31-1
Category:
Target:
Cat. No.: HY-N7955
CAS No.: 372096-70-3
Category:
Actaea heracleifolia (Kom.) J. Compton Tetracyclic Triterpenoids Terpenoids Ranunculaceae Plants
Target:
Cat. No.: HY-K6303
MCE Human iPSC/ESC Cardiomyocyte Induction Differentiation Kit is based on the classical GiWi system. By precisely modulating the Wnt/β-catenin signaling pathway in a temporally controlled manner (sequential activation and inhibition), the kit enables highly efficient directed differentiation of human pluripotent stem cells into cardiomyocytes. It is suitable for cardiac disease modeling, drug cardiotoxicity assessment, and mechanistic studies.
Cat. No.: HY-110247R
CAS No.: 433249-94-6
Target:
Research Areas:
TRAF-STOP inhibitor 6877002 (Standard) is the analytical standard of TRAF-STOP inhibitor 6877002 (HY-110247). This product is intended for research and analytical applications. TRAF-STOP inhibitor 6877002 is a selective CD40-TRAF6 interaction inhibitor. TRAF-STOP inhibitor 6877002 exerts anti-atherosclerotic activity by blocKing the CD40-TRAF6 signaling pathway, inhibiting classical monocyte activation, leukocyte recruitment, and macrophage activation and migration. TRAF-STOP inhibitor 6877002 reduces the phosphorylation levels of signaling intermediates in the canonical NF-κB pathway .
Cat. No.: HY-187366
PDGFRβ-IN-1 is an orally active PDGFRβ inhibitor with an IC50 of 3.9 nM against human PDGFRβ. PDGFRβ-IN-1 selectively inhibits PDGFRβ, blocks its downstream signaling pathways, and promotes its degradation via a non-classical pathway. PDGFRβ-IN-1 inhibits cancer cell proliferation, migration and colony formation, and induces cancer cell apoptosis. PDGFRβ-IN-1 suppresses tumor growth in xenograft models. PDGFRβ-IN-1 can be used for the research of hepatocellular carcinoma .
Cat. No.: HY-175445
CAS No.: 2417369-99-2
Research Areas:
GNE-5472 is a potent bifunctional ERα PRRTAC degrader, with its E3 ligand being a pan-IAP antagonist. GNE-5472 antagonizes cIAP1/2, activating the non-classical NF-κB pathway, resulting in a significant upregulation of TNFα expression. GNE-5472 inhibits the proliferation of breast cancer cells and induces cell apoptosis. GNE-5472 can be used for the study of breast cancer .
Cat. No.: HY-180373
CAS No.: 19160-62-4
WR 30090 (Compound 37) is a broad-spectrum antimalarial agent that does not rely on the classical antifolate pathway. WR 30090 exhibits strong activity against a variety of chloroquine-sensitive and resistant Plasmodium falciparum strains, especially the highly resistant Vietnamese strain. WR 30090 shows high activity in mouse malaria tests, with a minimum effective dose of 5 mg/kg and a minimum cure dose of 20 mg/kg. WR 30090 can be used for research on acute malaria .
Cat. No.: HY-P992456
Target:
Research Areas:
SAR-443809 is a monoclonal antibody targeting complement factor Bb that inhibits the alternative complement pathway. SAR-443809 blocks the cleavage of C3 and factor B via selective binding to the activated form factor Bb, with a KD of 7.3 nM for human factor Bb. SAR-443809 inhibits the amplification loop of the alternative complement pathway and C3 activation, reduces C3b deposition, and blocks the activation of pathways associated with intravascular and extravascular hemolysis. SAR-443809 can be used for research on hematological and renal disorders mediated by abnormal alternative complement pathway activity .
Cat. No.: HY-N17326
CAS No.: 242794-72-5
Target:
Research Areas:
Solasulfone (Solapsone; Sulfetrone) is an inhibitor of complement protein C1q and β-lactamase. Solasulfone also acts as a chemotherapeutic agent and can be used in cancer research .
Cat. No.: HY-138195
CAS No.: 1361198-79-9
NEO212 is an orally active, blood-brain barrier permeable conjugate of Temozolomide (TMZ) (HY-17364) and Perillyl Alcohol (POH) (HY-N7000), with potent anticancer activity. NEO212 overcomes classical TMZ resistance and DNA alkylation by depleting MGMT. By inhibiting the FAK/Src signaling pathway, NEO212 reduces the production of MMP2 and MMP9, induces mesenchymal-epithelial transition, and inhibits the migration, invasion and tumor progression of glioma stem cells. NEO212 disrupts autophagy flux to enhance mitochondrial apoptosis; it induces differentiation of acute myeloid leukemia (AML) cells into macrophages and proliferation arrest .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
